Top

Molecular Cancer

Published in:

Open Access 01-12-2012 | Research

Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis

Authors: Zujun Sun, Qingqiong Luo, Dongxia Ye, Wantao Chen, Fuxiang Chen

Published in: Molecular Cancer | Issue 1/2012

Abstract

Background

Toll-like receptor 4 (TLR4) is expressed on immune cells as a sensor that recognizes lipopolysaccharide (LPS), a microbial conserved component. It has recently been determined that the expression of TLR4 is also found in various types of tumor cells. Cisplatin is a widely used chemotherapeutic agent for oral squamous cell carcinoma (OSCC) treatment. However, the mechanisms responsible for cisplatin resistance are not well understood.

Results

The present study was designed to elucidate the role of TLR4 expression in human OSCC regarding immune escape and apoptotic resistance to cisplatin. TLR4 and the myeloid differentiation primary response gene 88 (MyD88) were highly expressed in OSCC cell lines. Upon LPS stimulation both NF-κB and p38 MAPK pathways were activated in OSCC cell lines, followed by the production of large quantities of IL-6, IL-8 and VEGF compared with human immortalized oral epithelia cells (HIOECs). OSCC cell lines were found to be resistant to cisplatin-mediated apoptosis after pretreatment with LPS.

Conclusions

Our results suggested that TLR4 was functionally expressed in human OSCC cells and development of resistance to cisplatin in human OSCC might occur through the mechanism involving TLR4 and its signaling pathway. Suppression of TLR4 and its signaling pathway might thus elevate sensitivity to cisplatin and potentially help improve the prognosis of patients with OSCC.

Available only for authorised users

Kademani D: Oral cancer. Mayo Clin Proc. 2007, 82: 878-887. 10.4065/82.7.878CrossRefPubMed

Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74CrossRefPubMed

Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z: Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 2007, 13: 5280-5289. 10.1158/1078-0432.CCR-07-1378PubMedCentralCrossRefPubMed

Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801. 10.1016/j.cell.2006.02.015CrossRefPubMed

Kawai T, Akira S: Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007, 13: 460-469. 10.1016/j.molmed.2007.09.002CrossRefPubMed

Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 2004, 4: 499-511. 10.1038/nri1391CrossRefPubMed

Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126CrossRefPubMed

Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005, 65: 5009-5014. 10.1158/0008-5472.CAN-05-0784CrossRefPubMed

He W, Liu Q, Wang L, Chen W, Li N, Cao X: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007, 44: 2850-2859. 10.1016/j.molimm.2007.01.022CrossRefPubMed

10.

Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL: Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009, 69: 3105-3113.PubMedCentralCrossRefPubMed

11.

Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL: TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009, 28: 4353-4363. 10.1038/onc.2009.289PubMedCentralCrossRefPubMed

12.

O'Neill LA: When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity. 2008, 29: 12-20. 10.1016/j.immuni.2008.06.004CrossRefPubMed

13.

Macagno A, Molteni M, Rinaldi A, Bertoni F, Lanzavecchia A, Rossetti C, Sallusto F: A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J Exp Med. 2006, 203: 1481-1492. 10.1084/jem.20060136PubMedCentralCrossRefPubMed

14.

Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N: Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000, 10: 33-41.CrossRefPubMed

15.

Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB: An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003, 63: 3066-3068.PubMed

16.

Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV: Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003, 3: 1-19.CrossRefPubMed

17.

Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV: TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene. 1999, 229: 75-81. 10.1016/S0378-1119(99)00042-6CrossRefPubMed

18.

Clinchy B, Fransson A, Druvefors B, Hellsten A, Hakansson A, Gustafsson B, Sjodahl R, Hakansson L: Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma. Cancer. 2007, 109: 1742-1749. 10.1002/cncr.22623CrossRefPubMed

19.

Vaquero J, Campbell JS, Haque J, McMahon RS, Riehle KJ, Bauer RL, Fausto N: Toll-like receptor 4 and myeloid differentiation factor 88 provide mechanistic insights into the cause and effects of interleukin-6 activation in mouse liver regeneration. Hepatology. 2011, 54: 597-608.PubMedCentralCrossRefPubMed

20.

Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T: Azzam Eel D, Khalifa A: Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004, 37: 363-369. 10.1016/j.clinbiochem.2004.01.014CrossRefPubMed

21.

Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM, Gorelik E: Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006, 102: 244-251. 10.1016/j.ygyno.2005.12.011CrossRefPubMed

22.

McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, Connolly DT, Robertson DM: Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994, 344: 235-236. 10.1016/S0140-6736(94)93001-5CrossRefPubMed

23.

Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC: Mechanisms of tumor evasion. Cancer Treat Res. 2005, 123: 61-88. 10.1007/0-387-27545-2_3CrossRefPubMed

24.

Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z: Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002, 101: 415-422. 10.1002/ijc.10632CrossRefPubMed

25.

Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998, 92: 4150-4166.PubMed

26.

Park HJ, Park OJ, Shin J: Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells. Exp Mol Med. 2005, 37: 524-532.CrossRefPubMed

27.

Chen R, Alvero AB, Silasi DA, Mor G: Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007, 57: 93-107. 10.1111/j.1600-0897.2006.00441.xCrossRefPubMed

28.

Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003, 22: 90-97. 10.1038/sj.onc.1206056CrossRefPubMed

29.

Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, Tanaka M: Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene. 2000, 19: 1225-1231. 10.1038/sj.onc.1203427CrossRefPubMed

30.

Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K, Tsuneyoshi M, Tanaka M, Katano M: Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 2006, 66: 7041-7049. 10.1158/0008-5472.CAN-05-4588CrossRefPubMed

31.

Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, Ferri LE: LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. 2011, 71: 1989-1998. 10.1158/0008-5472.CAN-10-2833CrossRefPubMed

32.

Qian Y, Deng J, Xie H, Geng L, Zhou L, Wang Y, Yin S, Feng X, Zheng S: Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol. 2009, 135: 379-386. 10.1007/s00432-008-0478-zCrossRefPubMed

33.

Zhong LP, Yang X, Zhang L, Wei KJ, Pan HY, Zhou XJ, Li J, Chen WT, Zhang ZY: Overexpression of insulin-like growth factor binding protein 3 in oral squamous cell carcinoma. Oncol Rep. 2008, 20: 1441-1447.PubMed

34.

Zhong LP, Pan HY, Zhou XJ, Ye DX, Zhang L, Yang X, Chen WT, Zhang ZY: Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol. 2008, 53: 443-452. 10.1016/j.archoralbio.2007.12.002CrossRefPubMed

Title: Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis
Authors: Zujun Sun
Qingqiong Luo
Dongxia Ye
Wantao Chen
Fuxiang Chen
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-11-33

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth

IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation

Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation

The small GTPase RhoG mediates glioblastoma cell invasion

MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma

Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer